Cytogen **Biotechknüller der Zukunft** - 500 Beiträge pro Seite

[Hajo3]

Hi Biotech-Fans,
auch die Aktie der Cytogen hat wieder enormes Aufholpotential. Sie liegt momentan zw. 8-9 Euro und sollte wohl in den nächsten Wochen in Richtung 12-15 Eur marschieren.

Sie hat viele interessante Produkte in der Pipeline und zudem seit heute noch eine Zusammenarbeit mit Progenics Pharm. abgeschlossen.

Hier die Nachricht in englich:

Press Release
SOURCE: Progenics Pharmaceuticals, Inc.
Progenics and Cytogen Select Therapeutic Prostate Cancer Vaccine for Human Testing
LAKE TAHOE, Nev., Sept. 25 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX - news) and Cytogen Corporation (Nasdaq: CYTO - news) announced a new vaccine candidate that the companies will develop for the treatment of prostate cancer. The vaccine is directed against prostate specific membrane antigen (PSMA), a unique protein found on the surface of prostate cancer cells, and is designed to stimulate a patient`s immune system to recognize and destroy the cancer cells. The preclinical findings were reported at the 7th Annual CaP CURE Scientific Retreat, a gathering of more than 350 of the world`s leading prostate cancer researchers. This in vivo immunotherapy program is being conducted under a joint venture between Progenics and Cytogen.

The new vaccine is a genetically-engineered, or recombinant, form of the PSMA protein that comprises a portion of the protein that resides on the surface of prostate cancer cells and is fully accessible to the immune system. It is believed that the recombinant PSMA protein can be produced at large scale in a form suitable for human clinical testing. A highly purified form of the recombinant PSMA protein will be combined with a potent immunological stimulant, or adjuvant, to form the final vaccine product. The findings were described in an oral presentation by William C. Olson, Ph.D., Senior Director of Research & Development at Progenics.

``Based on our recent scientific advances, we have successfully produced a vaccine candidate that faithfully mimics the PSMA structure expressed on prostate cancer cells,`` said Dr. Olson. ``We believe that such a vaccine has the potential to induce an immune response in patients that is capable of eliminating prostate cancer cells. We expect to begin Phase I clinical studies next year.``

In addition to the recombinant PSMA protein vaccine approach described above, Progenics and Cytogen are also pursuing in parallel a vaccine strategy that utilizes novel and proprietary viral vectors which are designed to deliver the PSMA gene to the immune system. In animal studies, the vaccines have generated potent and specific immune responses to cell-surface PSMA. In addition to their two vaccine programs directed at stimulating a patient`s immune system against his own cancer, Progenics and Cytogen have a therapeutic antibody program that includes ``naked``, radiolabelled, and toxin-conjugated monoclonal antibodies directed specifically at PSMA. The companies anticipate that a viral vaccine candidate as well as antibody-based therapies could also be tested in the clinic next year.

The PSMA gene was first discovered by scientists at Memorial Sloan-Kettering Cancer Center in New York City. PSMA is a cell-surface protein abundantly expressed on prostate cancer cells and therefore is an attractive target for vaccine and antibody-based cancer immunotherapies. Further work demonstrated that PSMA is also present at high levels on newly formed blood vessels (neovasculature) needed for the growth and survival of many types of solid tumors. These observations suggest that if PSMA-targeted therapies exhibit anti-angiogenesis effects, they may be valuable in treating a broad range of cancers.

Progenics Pharmaceuticals, Inc. is a biopharmaceutical company focusing on the development and commercialization of products for the treatment and prevention of cancer, viral, and other life-threatening diseases. The Company`s most advanced product, GMK, is a cancer vaccine in pivotal Phase III clinical trials for the treatment of malignant melanoma. A second cancer vaccine, MGV, with broad application to a variety of cancers, is entering Phase II trials. GMK and MGV are being developed in collaboration with Bristol-Myers Squibb Company. The Company`s lead HIV product, PRO 542, has completed two Phase I/II clinical trials, and two follow-on HIV products, PRO 367 and PRO 140, are preparing to commence Phase I/II trials. Progenics also has collaborations with F. Hoffmann-La Roche Ltd in the area of HIV co-receptors, and with American Home Products and Pharmacopeia, Inc. focusing on HIV attachment and fusion. The Company is also developing a novel small-molecule antioxidant, DHA, to treat stroke and other disorders.

Cytogen Corporation is a biopharmaceutical company in Princeton, NJ whose mission is setting new standards in cancer care. Its two principal lines of business, proteomics and oncology, are built upon its expertise in antibodies and molecular recognition and are directed to development of novel products for the diagnosis, imaging, staging and treatment of cancer and a proteomics-driven drug discovery platform. The Company`s cancer management franchise currently comprises four FDA-approved products: ProstaScint®, used to image the extent and spread of prostate cancer; BrachySeed(TM) implants for prostate cancer therapy; OncoScint CR/OV®, a diagnostic imaging agent for colorectal and ovarian cancer; and Quadramet®, for the relief of cancer-related bone pain. The Company has established a pipeline of product candidates based on its proprietary antibody and prostate specific membrane antigen, or PSMA, technologies, and holds worldwide exclusive license to PSMA. The Company also has U.S. marketing rights to the late-stage product candidate Combidex®, a magnetic resonance imaging agent being developed by Advanced Magnetics for the detection of lymph node metastases. The Company`s wholly owned subsidiary, AxCell Biosciences Corporation, is developing a proprietary protein pathway database as a drug discovery and development tool for the pharmaceutical and biotechnology industries. AxCell Biosciences has agreed to enter into a collaboration with the Institute for Systems Biology to elucidate aberrations in protein signaling pathways underlying the metastatic spread of prostate cancer.

This press release contains forward-looking statements. Any statements contained herein that are not statements of historical fact may be forward-looking statements. The words `anticipates,` `plans,` `expects` and similar expressions identify forward-looking statements. Such forward-looking statements involve risks and uncertainties which may cause the companies` actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. Such factors include, among others, the uncertainties associated with product development, the risk that clinical trials will not commence when or proceed as planned, the risks and uncertainties associated with dependence upon the actions of the companies` corporate, academic and other collaborators and of government regulatory agencies, the risk that products that appeared promising in early clinical trials do not demonstrate efficacy in larger-scale clinical trials, the uncertainty of future profitability and other factors set forth more fully in the companies` Annual Reports on Form 10-K for the fiscal year ended December 31, 1999 and other periodic filings with the Securities and Exchange Commission. In particular, there can be no assurance that the companies` PSMA programs will result in a commercial product. The companies do not have a policy of updating or revising forward-looking statements, and thus it should not be assumed that the companies` silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements.

Contact: Ronald J. Prentki, President of Progenics Pharmaceuticals, 914-789-2800, [e-mail]; or Richard W. Krawiec, Ph.D., Vice President Investor Relations and Corporate Communications of Cytogen Corporation, 609-750-8289; or Renee Connolly, Media, Noonan-Russo Communications, 212-696-4455 ext. 227, [e-mail], for Progenics Pharmaceuticals

SOURCE: Progenics Pharmaceuticals, Inc.



CYTOGEN CORP. SHARES DL -, 01
Berlin 871813 8,00 G +0,30 +3,90% 13.050,00 19:42/25.09.
Frankfurt 871813 9,00 B +1,00 +12,50% 5.535,00 19:38/25.09.
XETRA 871813 9,95 +0,00 +0,00% 995,00 13:52/14.09.
Stuttgart 871813 8,00 B +0,20 +2,56% - 12:28/25.09.
München 871813 7,75 -T -0,25 -3,12% - 09:12/25

Heute legte sie teils 12% zu.

Also auch hier sehe ich gutes Potential nach oben.
Weitere News werden folgen.
mein KZ: 15-20 Euro

Gruß Hajo

[sacrow]

CYTO am besten in USA kaufen, gestern wahrscheinlich wieder Tief nachgoood news erreicht. Nachbörslich ist bid/ask angezogen. Er steht jetzt aktuell bei 6 3/16 x 6 5/16, volumen war gestern in USA 874.000
Tief lag kurz vor Börsenschluss im bid bei 6

Target für 1 Jahr: 30 Dollar

gruss

sacrow

[defizit1]

Hi!
Hat hier irgendjemand noch mehr uber cytogen?
Wieviel Produkte sind denn in der Pipeline? In welchen Bereichen? Sind sie nue auf ein Medikament gestuetzt?
Besten Dank im voraus.
defizit1

[Amhairgin]

Schau auf http://recap.com/mainweb.nsf/HTML/clinical+frame?OpenDocumen… nach. Ich denke, der Tip hilft wirklich weiter - und er stammt - pfui - aus dem AKTIONÄR!!!

[defizit1]

@amhairgin
Besten Dank - werde sofort auf der Seite nachlesen . Das mit dem Aktionär will ich aber nicht gelesen haben ;-)

[Hajo3]

Hi,
gestern legte Cytogen in den USA wieder knapp 8% 0,4 Dollar zu. Es könnte bald wieder in höhere Regionen aufgebrochen werden.
Ich halte Cytogen als sehr interessant und aussichtsreich. Über www.cytogen.com gelangt man zur Cytogen-Homepage und zur Produktpipeline. Sie sieht wirklich gut aus. Schaut mal nach.

Hier der akt. Börsenstand.
CYTOGEN CORP
Nasdaq 232824102 6,5625 +0,4375 +7,14% 3,71 Mio. 21:59/28.09.
CYTOGEN CORP. SHARES DL -, 01

XETRA 871813 9,95 +0,00 +0,00% 995,00 13:52/14.09.
Berlin 871813 7,00 G +0,00 +0,00% - 09:29/29.09.
Stuttgart 871813 7,20 G +0,20 +2,86% - 09:23/29.09.
München 871813 7,45 +0,45 +6,43% 745,00 10:06/29.09.
Frankfurt 871813 7,45 +0,35 +4,93% 745,00 09:00/29.09


Hajo

[CaptainChaos]

Auf der Suche nach noch unentdeckten Biotechperlen, bin ich auf CYTO gestossen. Bereits drei Produkte sind durch die FDA geprüft und zugelassen, werden aber noch nicht vermarktet. Aus dem nachfolgenden Text ergibt sich eine strategische Allianz u.a. mit DOW Chemical als Pharma - Riese. Bei einem Einstiegskurs von derzeit 6,50 Euro sehe ich ein großes Potential.Überzeugend ist auch die strateg. Alliant mit Progenics. Nachfolgend auszüge aus der Homepage von CYTO:

www.cytogen.com




Strategic Alliances


Progenics Pharmaceuticals, Inc.
In 1999, we entered a joint venture with Progenics Pharmaceuticals, Inc. to develop products utilizing our proprietary PSMA technology. The first of these products, currently under development, is a therapeutic prostate cancer vaccine utilizing a gene-based approach. Our current plans are that this approach, if successful in pre-clinical development, will proceed to human trials by early 2001. We are also developing through this venture antibody based immunotherapy for prostate cancer. We believe that these drugs, if successfully developed, could play an important role in the treatment or prevention of advanced prostate cancer. We believe there are significant unmet needs for treatment of this disease.

The Dow Chemical Company
In March 1993, we obtained an exclusive license from The Dow Chemical Company to North American rights to use Quadramet as a therapeutic radiopharmaceutical for metabolic bone disease or tumor regression for cancer caused by metastatic or primary cancer in bone in humans, and for the treatment of disease characterized by osteoblastic response in humans. In November 1998, Dow also extended our exclusive rights for use of Quadramet in treating advanced rheumatoid arthritis to Europe, Japan and other countries in addition to North America.

Memorial Sloan-Kettering Cancer Center
In 1993, we began a development program with Memorial Sloan-Kettering Cancer Center involving PSMA and our proprietary monoclonal antibody. In November 1996, we exercised an option for and obtained an exclusive worldwide license to this technology.

Molecular Staging, Inc.
We have entered into a letter of intent to obtain an exclusive, world-wide license from privately held Molecular Staging, Inc. for technology to be used in developing in vitro diagnostic tests utilizing PSMA and PSA. We anticipate that the novel technology applications in conjunction with our technology, may allow entry into the domestic market for PSA-based testing.

Elan Corp. plc
We entered into a license agreement granting Elan worldwide rights to a group of peptides and associated technology for orally administered drugs that are transported across the gastrointestinal epithelium, as well as rights to other orally delivered drugs derived from the research program. Elan is responsible for the further development and commercialization of this technology. We are entitled to royalties from sales of any product developed and commercialized based on this technology.





Products




We have three marketed products, each of which have been approved by the FDA: ProstaScint, used as an imaging agent in the diagnosis of prostate cancer; OncoScint CR/OV, used as a diagnostic imaging agent of colorectal and ovarian cancer; and Quadramet, used for relief of bone pain from cancer that has spread to the bone from the primary tumor.



Cancer diagnostic imaging products


Our cancer diagnostic products, ProstaScint® and OncoScint CR/OV®, are monoclonal antibody-based imaging agents for prostate, colorectal and ovarian cancers. These products utilize our proprietary targeted delivery system, employing whole monoclonal antibodies, which directs the radioisotope Indium 111 to malignant tumor sites. A radioisotope is an element which, because of nuclear instability, undergoes radioactive decay and emits radiation. The imaging products are supplied to hospitals, diagnostic imaging centers and radiopharmacies.

During an imaging procedure, the radiolabeled monoclonal antibody product is administered intravenously into the patient. The antibody travels through the bloodstream and binds to specific antigens expressed by the tumors being studied. The radioactivity from the isotope that has been attached to the antibody can be detected from outside the body by a gamma camera. Gamma cameras are universally found in all nuclear medicine departments. The image captured by the camera identifies the existence, location and extent of the radio-labelled pharmaceutical thus identifying the sites of tumor. Based on clinical studies conducted to date by physicians on our behalf, the imaging agents may provide new and useful information not available from other diagnostic modalities regarding the existence, location and extent of a specific disease throughout the body. We believe that this information has the potential to affect the way physicians manage their patients? individual treatments.


ProstaScint®


ProstaScintâ is a diagnostic monoclonal antibody linked to Indium 111 which specifically targets PSMA. Due to the selective expression of PSMA, the ProstaScint imaging procedure can detect the extent and spread of prostate cancer in the body. ProstaScint is approved by the FDA for marketing in two clinical settings: as a diagnostic imaging agent in newly diagnosed patients with biopsy-proven prostate cancer thought to be clinically localized after standard diagnostic evaluation and who are at high risk for spread of their disease to pelvic lymph nodes and for use in post-prostatectomy patients in whom there is a high suspicion that the cancer has recurred.

According to the American Cancer Society, about 179,000 American men were diagnosed with prostate cancer in 1998, of whom approximately 20% are at high risk for metastatic spread of their disease. In addition, estimates indicate that in 1999, 40,000 to 60,000 patients previously treated for prostate cancer developed symptoms of recurrent cancer which had not yet progressed to the point of skeletal involvement. We believe that there are approximately 75,000 to 100,000 patients with prostate cancer in the United States who are candidates, based on current indications, to receive a ProstaScint scan each year. We believe that the potential market for ProstaScint is over $50 million in the United States.

When deciding on an initial course of therapy for prostate cancer, physicians must first determine the extent of disease in the patient. The accuracy of this information is vital in deciding upon an appropriate course of therapy. Prior to the availability of ProstaScint, determining whether newly diagnosed disease was limited to the prostate or had spread beyond the gland was based upon statistical inference from the biopsy appearance of the tumor and the patient?s serum level of PSA. Conventional imaging methods are all relatively insensitive because they rely on identifying significant changes to normal anatomic structure to indicate the presence of disease. The ProstaScint disease scan images are based upon expression of the PSMA molecule and, therefore, can identify disease not readily detectable with conventional procedures.

In the United States, following initial therapy, prostate cancer patients are monitored to ascertain changes in the level of PSA. In this setting, a rise in PSA is evidence of recurrence of the patient?s prostate cancer. Knowledge of the extent and location of disease recurrence is important in choosing the most appropriate form of treatment. The National Comprehensive Cancer Network, a consortium of leading cancer hospitals, recently included ProstaScint in its Practice Guidelines for Prostate Cancer. These guidelines are published to serve as the practice standard for the oncology community.

We also believe that ProstaScint may be useful for imaging the extent of prostate cancer within the prostate gland. This information may be useful to help guide specific treatments such as prostate brachytherapy or highly targeted external beam radiation. Brachytherapy is a treatment which implants radiation sources into the site of the tumor; while external beam radiation utilizes a beam of radiation directed at the cancer from a source outside the body. We estimate that approximately half of newly diagnosed prostate cancer patients will undergo a form of radiation treatment. The current generation of imaging technologies enables physicians to view ProstaScint scans incorporated with conventional imaging modalities. We believe these technologies will create greater acceptance of ProstaScint. There are no other agents approved for the imaging and diagnosis of prostate cancer.


OncoScint®


OncoScintâ is approved by the FDA for single use with other appropriate, commercially available diagnostic tests, to locate malignancies outside the liver in patients with known colorectal or ovarian cancer. OncoScint CR/OV is also approved for sale in eleven European countries and Canada. To date, OncoScint CR/OV has not realized substantial sales. We believe this product is effective in imaging both primary and metastatic colorectal and ovarian tumors. However, this product has not yet been widely adopted by physicians for patients with these conditions. We market OncoScint CR/OV in the United States directly through our own sales force. The market for OncoScint CR/OV for colorectal cancer diagnosis has been negatively affected by positron emission tomography, or "PET", scans. The sensitivity of the PET scan in colon cancer appears to be similar or higher than the OncoScint CR/OV scan. However, PET studies are very expensive and available only at highly specialized institutions. We are emphasizing marketing of OncoScint CR/OV for the recurrent ovarian setting as an aid in determining whether second look surgery, following initial surgery, is advisable.


Quadramet®




Quadrametâ a proprietary cancer therapeutic agent, is approved by the FDA for the relief of pain in patients with metastatic bone lesions that image on conventional bone scan, a routinely performed nuclear medicine procedure. Quadramet consists of a radioactive isotope, Samarium 153 , which emits beta radiation, and a chelating agent, EDTMP, which targets the drug to sites of new bone formation.

Once tumors have metastasized to the skeleton, they continue to grow and cause destruction of the adjacent bone. This erosion of bone stimulates new bone formation which encircles the metastatic tumor. By targeting these areas of bone formation, Quadramet delivers site-specific radiation which may result in significant pain reduction.

According to American Cancer Society and National Cancer Institute statistics, approximately 600,000 new cases of cancer that typically metastasize to bone occurred in the United States in 1997. We believe that over 200,000 patients each year will suffer from bone pain that is severe enough to require intervention. Based on this information, we believe that the market for Quadramet is $80 million in the United States based on 20% of this patient population.

Quadramet has many characteristics which we believe are advantageous for the treatment of cancer bone pain, including early onset of pain relief, lasting up to four months with a single injection; predictability of recovery from bone marrow toxicity; ease of administration and length of pain relief. In addition, due to its pharmacokinetic properties, the radioactive plasma half-life is only five to six hours. Quadramet is administered as a single intravenous injection on an outpatient basis and directly targets sites of new bone formation which include those areas in the skeleton that have been invaded by metastatic tumors. Quadramet exhibits high and very selective uptake in bone with little or no detectable accumulation in soft tissue.

Berlex has initiated a Phase III clinical trial to evaluate the extension of the use of Quadramet to patients whose bone metastases can be visualized on conventional bone scan, but who are not yet experiencing pain from these metastases. We believe earlier use in the care of cancer patients could expand the potential market for Quadramet significantly. Our continuation of these trials will depend upon their progress and success of the trial, and on decisions by our marketing partner Berlex to continue to fund the trial. If this trial is successful, we plan to seek expansion of the FDA approved indication of Quadramet for this therapeutic use in delaying progression of the onset of pain.

Current competitive treatments for severe bone cancer pain include narcotic analgesics, external beam radiation therapy, Metastron and Novantrone.

The first non-cancer use of Quadramet under investigation is the treatment of patients with refractory rheumatoid arthritis. We believe Quadramet can target the diseased joints and provide a high but localized dose of radiation to the area which may relieve the symptoms of refractory rheumatoid arthritis. We are determining how to proceed with this possible use based upon analyzing the data from a Phase I dose escalation study.

[swietel]

ICH BIN SEIT LÄNGEREM IN CYTOGEN INVESTIERT UND WEISS AUS ZUVERLÄSSIGER QUELLE DAS SOBALD DIE VERMARKTUNG BEGINNT LOCKER 1000-2000% DRIN SIND.

[IchWeissDassIchNichtsWeiss]

Hi,

bin seit etwa einem Jahr in Cytogen investiert. Cytogen hat wohl gute Produkte, das Management läßt allerdings zu wünschen übrig. Die schwache Kursentwicklung der letzten 3 Jahre ist darauf zurückzuführen. Die Analystenmeinungen sind auch geteilt, während PROHOST und BechonBiotech Cytogen in ihrem Musterdepot haben, hält Medical Investor nicht viel von Cytogen.

Spekulativ ist Cytogen mittelfristig aufgrund seiner Proteomicsforschug interessant!

[Indoflitzer]

Hi Sacrow,
Du schreibst in den USA ordern.
Weist Du da einen einigermassen kostengünstigen Weg.
Wenn ich das richtig sehe kostet das bei Consors über 100.-DM.
Indoflitzer

[tabaan123]

hallo captain chaos & all:
wer kann mir denn sagen, wann eine vermarktung der 3 produkte angestrebt ist, und durch wen?
vielleicht weiss @swietel näheres?
wäre über infos dankbar.
liebe grüsse
tabaan

[Hajo3]

Hi tabaan,
wann es mit der Vermarktung soweit ist, kann man wohl noch nicht sagen. Aber ich meine aufgrund der guten Pipeline ist Cyto eine große Chance.

Also investieren oder inestiert bleiben.
Näheres siehe unter
http://recap.com/mainweb.nsf/HTML/clinical+frame?OpenDocumen…
Hier kannst du alle Biotech-Firmen auf ihre momentane Pipeline und zugelassenen sowie Phasen der Produkte abfragen.
Absolut hilfreiche Web.

Gruß Hajo

[tabaan123]

lieber hajo,
vielen dank für deine antwort und die post (hab´s heute erst gesehen)
bleibe auf jeden fall investiert, zum zocken gibt es ja derzeit genügend werte, ist aber nicht mein ding.
liebe grüsse
tabaan

[CaptainChaos]

Heute kommen die Quartalszahlen. Prognosen im Board ?

[extremo]

11/13/00 - Cytogen Reports Third Quarter 2000 Results and Corporate Update


PRINCETON, N.J., Nov 13, 2000 /PRNewswire via COMTEX/ -- Cytogen Corporation (Nasdaq: CYTO) today reported its consolidated financial results for the third quarter and nine-month period ending September 30, 2000. For the third quarter of 2000, the Company reported a net loss and net loss per share of $16.7 million and $0.23, respectively, compared to a net loss of $1.2 million, or $0.02 per share for the quarter ending September 30, 1999. The third quarter 2000 loss includes a one-time, non-cash charge of $13.1 million or $0.18 per share related to the acquisition of marketing rights to two novel product candidates with broad application in oncology, Combidex and Code 7228. Without the one-time licensing charge, the third quarter 2000 net loss and net loss per share would have been $3.4 million, or $0.05, respectively. For the nine-month period ended September 30, 2000, the net loss and net loss per share were $21.2 million and $0.29, (inclusive of the one-time charge of $13.1 million) respectively compared to net loss of $539,000 or $0.01 per share for the comparable period last year.

"One of our main objectives in 2000 was to build a dedicated oncology sales force and a product pipeline in oncology," said H. Joseph Reiser, Ph.D., Cytogen`s President and Chief Executive Officer. "We believe we have made significant strides in accomplishing both of these goals. During the third quarter, we invested in our future by obtaining U.S. marketing rights to two novel imaging agents with broad applications in oncology, Combidex and Code 7228. In addition, we also signed a definitive letter of intent for U.S. marketing rights to BrachySeed(TM) prostate cancer therapy, thus leveraging the investment we made in building a dedicated oncology sales force with a specialization in prostate cancer."

"Our other major focus was to expand the capabilities of our proteomics subsidiary, AxCell Biosciences," Dr. Reiser continued. "Our progress toward accomplishing this objective is particularly evident by the achievement of a sustainable automated process for high-throughput measurement of protein interactions. In this regard, our protein interaction database has grown substantially since the beginning of this year and we eagerly anticipate the launch of AxCell`s first product, the InterFunctional Proteomics Database(TM) next year."

Beginning in the third quarter 2000, the Company took over sole ProstaScint(R) marketing and selling responsibilities from its former partner, the Urological Division of C.R. Bard Co. ProstaScint sales showed a 24% sequential increase over the second quarter of 2000 as Cytogen`s sales force began focusing their sales efforts directly to urologists, oncologists and nuclear medicine specialists. Compared to last year, ProstaScint sales increased 12% versus the comparable third quarter. The Company believes that its investment in its sales force will continue to drive the growth of ProstaScint in future quarters.

Sales of Quadramet(R) increased 118% to $6.1 million for the three quarters in 2000 from the $2.8 million reported last year, resulting in higher royalty revenues for Cytogen. The sales increase is due to increased market penetration and acceptance since Quadamet`s relaunch by Berlex Laboratories in March of 1999. For the third quarter and year-to-date periods, royalty revenues were $523,000 and $1.5 million respectively, compared to $245,000 and $706,000, respectively, for the comparable periods of last year. Our marketing partner, Berlex Laboratories, continues to invest heavily in this product in order to expand its current indication for the relief of severe pain in cancer patients.

Revenues for the third quarter ended September 30, 2000 were $2.5 million compared to $2.3 million for the same period in 1999. For the nine-month period ended September 30, 2000, total revenues were $7.2 million compared to $9.1 million for the same period in 1999. The year-to-date decreases were primarily attributable to a licensing fee of $1.8 million recorded in the second quarter of 1999 for the licensing of certain applications related to prostate specific membrane antigen (PSMA) and the discontinuance of contract manufacturing services at the end of 1999 in connection with the sale of the Company`s manufacturing facility.

Total on-going operating expenses for the third quarter of 2000 were $6.1 million compared to $3.6 million in the same period of 1999. On-going operating expenses for the nine-month period ended September 30, 2000 were $15.5 million compared to $11.9 million in 1999. The year-to-date and third quarter increased expenditures principally reflect development efforts in the proteomics programs at AxCell Biosciences, increased marketing and sales efforts, and costs associated with the termination of the merger agreement with Advanced Magnetics, Inc. Acquisition of marketing and technology rights of $13.2 million represents a one-time charge related to the licensing of Combidex(R) and Code 7228 products from Advanced Magnetics, of which $13.1 million is non-cash. In 1999, the Company recorded a non-cash charge of $1.2 million for the acquisition of Prostagen, Inc.

In September, the Company received $6 million from the sale of 902,601 shares of Cytogen Common Stock to Acqua Wellington North American Equities Fund, Ltd. Cash, cash equivalents, and short-term investments as of September 30, 2000 were $14.2 million compared to $12.4 million as of December 31, 1999. In October, the Company also entered into a $70 million equity financing facility with Acqua Wellington. This financing facility provides Cytogen with the ability to access capital as needed to accelerate its proteomic and drug development programs as well as for general corporate purposes. Over the next 20 months, Cytogen may, at its discretion, sell additional shares of its common stock to Acqua Wellington pursuant to this financing facility at a small discount to market to be determined before each sale.

Sales and Marketing

Cytogen has signed a binding letter of intent with Draxis Health, Inc. to market and distribute BrachySeed for prostate cancer therapy in the U.S. The Company is currently negotiating definitive documents with Draxis which reflect of the terms of the letter of intent. Cytogen believes that BrachySeed is an excellent strategic fit within its product portfolio, as the target patient and physician audiences for ProstaScint and BrachySeed are the same. Pre-launch activities for BrachySeed are underway, including a completed exhibit at the annual meeting of radiation oncologists, scheduled Cytogen-sponsored educational programs, targeting key thought leaders in radiation oncology, urology and physics, and the training of the sales force. The Company expects to launch BrachySeed by the end of the year.

A recently published paper in the International Journal of Radiation Oncology reported using ProstaScint to guide delivery of more targeted radiation to prostate cancer cells. Clinicians combined ProstaScint images with computed tomography scans to locate the highest areas of tumor burden within the prostate gland and implanted radioactive seeds preferentially within these areas. The Company believes that radioimmuno-guided brachytherapy represents an important new use of ProstaScint that could be synergistic in driving product growth for both ProstaScint and BrachySeed therapy.

In December, the National Comprehensive Cancer Network (NCCN) plans to publish its Practice Guidelines for Prostate Cancer which include the use of ProstaScint in the staging and spread of this disease. The Company believes that with the publication of the NCCN guidelines ProstaScint is well positioned as a mainstream diagnostic and staging tool.

AxCell Biosciences

AxCell is creating the InterFunctional Proteomics Database(TM) (IFP Database) as its first product offering for an expected launch at end of the first quarter of 2001. InforMax, Inc., a leading supplier of bioinformatics information and AxCell`s marketing partner, is working with AxCell to develop the sales and marketing plan for the launch. The AxCell business model anticipates the sale of multi-year, non-exclusive subscriptions to the IFP Database as it evolves into a separate, stand-alone business unit.

InforMax is also preparing the software module for the IFP Database which is designed to permit users to analyze protein pathways, identify targets, and perform pharmacogenomic analysis at the protein level. AxCell researchers have integrated a series of automated and proprietary, laboratory procedures involving cloning, robotic sample manipulation, and computerized data recording into a sustainable, high-throughput commercializable process which measures protein/protein interactions at the current rate of approximately 10,000 per day.

AxCell`s initial goal is to map disease-oriented signal transduction pathways -- signals being transferred from the outside to inside of cell -- in the human proteome. While AxCell is nearing the completion of mapping of interactions of all currently known domain members in families such as WW, PDZ and SH3, AxCell plans to chart interactions of new domain families members as they are uncovered. AxCell is also examining additional families, such as SH2 and PTB domains which interact with proteins that have been modified after their initial expression, (e.g., post-translational modification) resulting in additional pathways and targets (e.g., those phosphorylated by protein kinases). By knowing all of the members of a given family, AxCell believes that it may be possible not only to pinpoint drug targets, but also to examine the potential toxicity or cross reactivity of a new drug lead before animal testing, thus providing earlier lead optimization at the protein level. Signal transduction pathways are associated with most diseases, including cardiovascular, central nervous system disorders, and cancer.

AxCell has agreed to form a collaboration with the Institute for Systems Biology, a research center in Seattle headed by Dr. Leroy Hood, initially to chart the protein-interaction changes in prostate cells that have become cancerous. AxCell plans to compare protein signaling pathways from patients with primary, soft tissue, bone metastases and normal prostate tissue to look for differences in protein signaling pathways. The Company believes that aberrations in protein pathways may be associated with metastatic prostate cancer, and that by pinpointing these changes it may be possible to identify specific targets that might halt the spread of cancerous cells.

AxCell and Molecular Staging, Inc. (MSI) have announced plans to investigate potential synergies between their technologies that may be useful in mapping protein pathways more rapidly and efficiently. MSI`s Rolling Circle Amplification Technology(TM) (RCAT) is a proprietary, highly sensitive and efficient amplification method for detecting the presence of target molecules micro-arrayed on a biochip. By combining AxCell`s domain-ligand interaction technology with MSI`s protein arrays, the two companies believe that they may be able to increase the rate of protein interaction measurements by up to 10 fold more than AxCell`s current rate of approximately 10,000 interactions per day. The experimental design for this ultra-high-throughput technology is currently underway. One goal is to express entire domain families on a single biochip as a tool for lead optimization in drug discovery.

Product Pipeline

Cytogen acquired exclusive U.S. marketing rights from Advanced Magnetics, Inc., to Combidex, a magnetic resonance imaging contrast agent for oncology and other applications. The Company also obtained exclusive U.S. rights to imaging agent Code 7228 for oncology applications. Combidex has received an approvable letter subject to certain conditions by the FDA, following a priority review. Code 7228 is expected to enter Phase II clinical development early next year. These product candidates leverage Cytogen`s expertise in oncology and imaging, which it gained via its ProstaScint and OncoScint CR/OV products. Combidex is a first-in-class agent for detection of lymph node metastases utilizing magnetic resonance imaging and represents a potential near-term, synergistic addition to Cytogen`s current line of innovative oncology products.

Prostate Specific Membrane Antigen

Cytogen is investing in a broad and integrated approach to develop novel therapeutic and diagnostic products based on prostate specific membrane antigen (PSMA), a unique protein abundantly expressed on the surface of virtually all primary and metastatic prostate cancer cells. During 2001, the Company and its joint venture partner, Progenics Pharmaceuticals, Inc., plan to file an Investigational New Drug Application (IND) to begin clinical trials of PSMA-based prostate cancer vaccines. Later in the year, the joint venture also expects to file an IND for antibody-based therapies in prostate cancer. The joint venture has announced the selection of a novel vaccine candidate directed against PSMA and designed to stimulate a patient`s immune system to recognize and destroy the cancer cells. The vaccine is a genetically engineered, or recombinant, form of the PSMA protein that comprises a portion of the protein that is highly expressed on the surface of prostate cancer cells. A purified form of the recombinant PSMA protein will be combined with a potent immunological stimulant, or adjuvant, to form the vaccine. The companies are also developing a viral vaccine candidate containing the PSMA gene. Novel viral vector and purified protein vaccines for use both individually and in prime-boost combinations are in late-stage pre-clinical development. In animal studies, the vaccines have generated potent and specific immune responses to cell-surface PSMA.

The joint venture has also developed a new generation of monoclonal antibodies that have potential utility in the treatment of prostate cancer and are directed against PSMA. The antibodies are being developed for therapy in "naked," radiolabelled and toxin-conjugated forms capable of selectively targeting and destroying PSMA-expressing cancer cells. The novel antibodies uniquely recognize the three-dimensional structure of PSMA as presented on cancer cells. Antibodies which bind to such "conformational" structures represent excellent candidates for therapy since they typically possess higher affinity and specificity for the target antigens than antibodies designed to recognize only segments or linear sequences, independent of the physical structure of the target. The joint venture expects to optimize the therapeutic utility of these antibodies in anticipation of human clinical testing.

Cytogen and MSI, have achieved proof of principle for an ultra-sensitive serum assay for PSA, a widely used marker for the screening and detection of prostate cancer. Results using a panel of five antibodies to PSA indicate that the new RCAT-based assay has a sensitivity of more than 200 fold greater than existing commercial blood tests. Cytogen believes that an ultra- sensitive assay might lead to earlier detection of prostate cancer, particularly in the recurrent setting. The next step is the selection of one antibody for commercial development. The companies are also in the process of applying RCAT technology to establish proof of principle for an ultra- sensitive assay for PSMA, which Cytogen believes may have greater prognostic value than the PSA test alone. The Company plans to market both assays on a biochip format.

Cytogen holds exclusive worldwide commercialization rights to PSMA from Memorial Sloan-Kettering Cancer Center and holds existing U.S. patents issued in 1996 and 1999. Cytogen has sub-licensed certain of these rights for in vivo immunotherapy to its PSMA joint venture with Progenics and to Northwest Biotherapeutics for ex vivo immunotherapy. Cytogen also has rights to additional U.S. patent applications covering broad PSMA technology. Cytogen intends to vigorously defend its intellectual property position from infringement.

Cytogen Corporation is a biopharmaceutical company in Princeton, NJ, whose mission is setting new standards in cancer care. Its two principal lines of business, proteomics and oncology, are built upon its expertise in antibodies and molecular recognition and are directed principally to development of novel products for the diagnosis, imaging, staging and treatment of prostate cancer and a proteomics-driven drug discovery platform. The Company`s cancer management franchise currently comprises four FDA-approved products: ProstaScint(R), used to image the extent and spread of prostate cancer; BrachySeed(TM) implants for prostate cancer therapy, OncoScint CR/OV(R), a diagnostic imaging agent for colorectal and ovarian cancer; and Quadramet(R), for the relief of cancer-related bone pain. The Company has established a pipeline of product candidates based on its proprietary antibody and prostate specific membrane antigen, or PSMA, technologies, and holds worldwide exclusive license to PSMA. Cytogen and its joint venture partner, Progenics Pharmaceuticals, are developing in-vivo immunotherapies for prostate cancer based on PSMA. The Company also has U.S. marketing rights to the late-stage product candidate Combidex(R), a magnetic resonance imaging agent being developed by Advanced Magnetics for the detection of lymph node metastases. The Company`s subsidiary, AxCell Biosciences Corporation, is developing a proprietary protein pathway database as a drug discovery and development tool for the pharmaceutical and biotechnology industries. For additional information on Cytogen, visit the Company`s web sites at www.cytogen.com and www.axcellbio.com.

This press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Information in this press release, which is not historical, is forward looking and involves a number of risks and uncertainties. Investors are cautioned not to put any undue reliance on any forward-looking statement. The Company`s actual results may differ materially from the Company`s historical results of operations and those discussed in the forward-looking statements for various reasons, including, but not limited to the Company`s ability to carry out its business plan, to successfully develop and commercialize acceptance of its products, ability to fund development necessary for existing products and for the pursuit of new product opportunities, the risk of whether products result from development activities, protection of its intellectual property portfolio, ability to integrate in-licensed products, ability to establish and successfully complete clinical trials where required for product approval, the risk associated with obtaining the necessary regulatory approvals, dependence on its partners for development of certain projects, the ability to obtain foreign regulatory approvals for products and to establish marketing arrangements in countries where approval is obtained, and other factors discussed in the Company`s 1999 Form 10-K and from time-to-time the Company`s other filings with the Securities and Exchange Commission.


Financial data to follow



CYTOGEN CORPORATION AND SUBSIDIARIES
(All amounts in thousands except per share data)
(Unaudited)



CONDENSED CONSOLIDATED BALANCE SHEETS



SEPTEMBER 30, DECEMBER 31,
2000 1999
ASSETS
Cash, Cash Equivalents and Short-Term
Investments $14,178 $12,394
Accounts Receivable, net 2,385 2,150
Inventories 631 685
Property and Equipment, net 2,032 1,997
Other Assets 1,470 1,379
_________ _________



Total Assets $20,696 $18,605
========= =========



LIABILITIES & STOCKHOLDERS` EQUITY
Accounts Payable & Accrued Liabilities $4,851 $5,478
Other Current Liabilities 161 162
Long - Term Liabilities 2,441 2,416
Stockholders` Equity 13,243 10,549
_________ _________



Total Liabilities & Stockholders` Equity $20,696 $18,605
========= =========



CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS



THREE MONTHS ENDED NINE MONT

[CaptainChaos]

Fazit:

Super Story und miese Quartalszahlen.

[CaptainChaos]

Zum Aufbauen!!

P.S. Ich bleibe drin.


Progenics and Cytogen Develop Antibodies to Treat Prostate Cancer

PR Newswire
November 10, 2000 7:30am
AMSTERDAM, Netherlands, Nov 10, 2000 /PRNewswire via COMTEX/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) and Cytogen Corporation (Nasdaq: CYTO) today announced their development of a new generation of monoclonal antibodies that have potential utility in the treatment of prostate cancer. These antibodies are directed against prostate specific membrane antigen (PSMA), a protein found on the surface of prostate cancer cells. The antibodies are being developed for therapy in "naked," radiolabelled and toxin-conjugated forms capable of selectively targeting and destroying PSMA-expressing cancer cells. The preclinical findings were reported here at the 11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy.

The novel antibodies uniquely recognize the three-dimensional structure of PSMA as presented on cancer cells. Antibodies which bind to such "conformational" structures represent excellent candidates for therapy since they typically possess higher affinity and specificity for the target antigens than antibodies designed to recognize only segments or linear sequences, independent of the physical structure of the target. The findings were described in a presentation by Robert J. Israel, M.D., Vice President of Medical Affairs at Progenics.

"The reactivity profile of our monoclonal antibodies makes them preferred therapeutic candidates over prior generation PSMA antibodies," said Dr. Israel. "We look forward to optimizing the therapeutic utility of these antibodies using the best available preclinical models of human prostate cancer in anticipation of human clinical testing."

In addition to the antibody strategy described above, the joint venture between Progenics and Cytogen is also pursuing a parallel development program for the development of therapeutic vaccines which target PSMA. Novel viral vector and purified protein vaccines for use both individually and in prime-boost combinations are in late stage pre-clinical development. In animal studies, the vaccines have generated potent and specific immune responses to cell-surface PSMA. The two vaccine programs are directed at stimulating a patient`s immune system to eradicate his own cancer. The companies anticipate that vaccine, as well as antibody-based therapies, could be tested in patients next year.

The PSMA gene was first discovered by scientists at Memorial Sloan-Kettering Cancer Center in New York City. PSMA is a cell-surface protein abundantly expressed on prostate cancer cells and therefore is an attractive target for vaccine and antibody-based cancer immunotherapies. Further work has demonstrated that PSMA is also present at high levels on newly formed blood vessels (neovasculature) needed for the growth and survival of many types of solid tumors. These observations suggest that if PSMA-targeted therapies exhibit anti-angiogenesis effects, they may be valuable in treating a broad range of cancers.

Progenics Pharmaceuticals, Inc. is a biopharmaceutical company focusing on the development and commercialization of products for the treatment and prevention of cancer, viral and other life-threatening diseases. The Company`s lead HIV product, PRO 542, has completed two Phase I/II clinical trials, and two follow-on HIV products, PRO 367 and PRO 140, are preparing to commence Phase I/II trials. Progenics also has collaborations with F. Hoffmann-La Roche Ltd in the area of HIV fusion co-receptors, and with American Home Products and Pharmacopeia, Inc. focusing on HIV attachment and fusion. The Company`s most advanced product, GMK, is a cancer vaccine in pivotal Phase III clinical trials for the treatment of malignant melanoma. The Company is also prepared to commence Phase II trials with a second cancer vaccine, MGV, with broad application to a variety of cancers. GMK and MGV are the subject of a collaboration with Bristol-Myers Squibb Company. The Company, with Cytogen Corporation, has formed a joint venture focusing on the development of cancer immunotherapies based on PSMA (Prostate Specific Membrane Antigen) technology. The Company is also developing a novel small-molecule antioxidant, DHA, to treat stroke and other disorders.

Cytogen Corporation is a biopharmaceutical company in Princeton, New Jersey whose mission is setting new standards in cancer care. Its two principal lines of business, proteomics and oncology, are built upon its expertise in antibodies and molecular recognition and are directed to development of novel products for the diagnosis, imaging, staging and treatment of cancer and a proteomics-driven drug discovery platform. The Company`s cancer management franchise currently comprises three FDA-approved products: ProstaScint(R), used to image the extent and spread of prostate cancer; OncoScint CR/OV(R), a diagnostic imaging agent for colorectal and ovarian cancerproduct. The companies do not have a policy of updating or revising forward-looking statements, and thus it should not be assumed that the companies` silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements.